EAU 2014 - Poster: A phase 2 trial of prostate specific membrane antigen antibody drug conjugate (PSMA ADC) in taxane-refractory metastatic castration-resistant prostate cancer (mCRPC)

STOCKHOLM, SWEDEN (UroToday.com) - Presented by D Petrylak,1 D Smith,2 L Appleman,3 M Fleming,4 A Hussain,5 R Dreicer,6 AO Sartor,7 N Shore,8 NJ Vogelzang,9 H Youssoufian,10 VA DiPippo,10 N Stambler,10 K Huang,10 RJ Israel10 at the 29th Annual European Association of Urology (EAU) Congress - April 11 - 15, 2014 - Stockholmsmässan - Stockholm, Sweden.

Petrylak poster EAU 2014 thumb


1Yale University, New Haven, CT; 2University of Michigan, Ann Arbor, MI; 3University of Pittsburgh, Pittsburgh, PA; 4Virginia Oncology Associates, Norfolk, VA; 5University of Maryland, Baltimore, MD; 6Cleveland Clinic, Cleveland, OH; 7Tulane University, New Orleans, LA; 8Carolina Urologic Research Center, Myrtle Beach, SC; 9Comprehensive Cancer Centers of Nevada, Las Vegas, NV; 10Progenics Pharmaceuticals, Inc., Tarrytown, NY


Click HERE to listen to Daniel P. Petrylak, MD discuss the key points from this poster